Literature DB >> 2509856

The "primary" antiphospholipid syndrome: major clinical and serological features.

R A Asherson1, M A Khamashta, J Ordi-Ros, R H Derksen, S J Machin, J Barquinero, H H Outt, E N Harris, M Vilardell-Torres, G R Hughes.   

Abstract

The antiphospholipid syndrome--the association of venous and/or arterial thromboses, often accompanied by thrombocytopenia in the presence of the antiphospholipid antibodies ("lupus anticoagulant" antibodies to cardiolipin)--is seen mainly in patients with systemic lupus erythematosus (SLE) and the closely related "lupus-like" disease, i.e., lupus patients not conforming to the 1982 revised American Rheumatism Association classification for SLE. It is also seen in a group of patients who do not manifest any of the major clinical or serologic features of SLE, the majority of whom do not appear to progress to classical lupus. A multicenter study of 70 of these patients is documented and their major clinical and serologic characteristics examined: They have been characterized as suffering from a "primary" antiphospholipid syndrome and present typically with a history of deep vein thromboses, often accompanied by pulmonary thromboembolism, which in a few is complicated by thromboembolic pulmonary hypertension, arterial occlusions (most commonly strokes), or fetal loss. The events are often recurrent and may be accompanied by hemocytopenias (thrombocytopenia and less frequently Coombs positivity and/or hemolytic anemia). They are often antinuclear antibody-negative and are always negative for antibodies to dsDNA and to ENA, typical serologic features of SLE. There may be a family history of SLE or a familial clotting tendency in a minority. The group of patients presented appears to be closely related, but distinctly separate from SLE.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509856

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  118 in total

1.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 2.  Antiphospholipid antibodies and cardiovascular disease.

Authors:  H L Beynon; M J Walport
Journal:  Br Heart J       Date:  1992-04

3.  Anticardiolipin antibodies and renovascular hypertension.

Authors:  E Rossi; C Sani; M Zini; M C Casoli; G Restori
Journal:  Ann Rheum Dis       Date:  1992-10       Impact factor: 19.103

Review 4.  Antiphospholipid antibodies and infections.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  2003-05       Impact factor: 19.103

Review 5.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 6.  Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients.

Authors:  R Cervera; R A Asherson; M L Acevedo; J A Gómez-Puerta; G Espinosa; G De La Red; V Gil; M Ramos-Casals; M García-Carrasco; M Ingelmo; J Font
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

Review 7.  Perioperative care for patients with rheumatic diseases.

Authors:  Bharath M Akkara Veetil; Tim Bongartz
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

Review 8.  'Overlap' syndromes.

Authors:  R Cervera; M A Khamashta; G R Hughes
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

9.  Antiphospholipid antibodies: which and when?

Authors:  R Cervera; J Font; M A Khamashta; G R Hughes
Journal:  Postgrad Med J       Date:  1990-11       Impact factor: 2.401

Review 10.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.